Antibodies and polypeptides directed against cd127
AssigneeOse Immunotherapeutics
InventorsNicolas POIRIER, Caroline MARY, Bernard VANHOVE, Virginie THEPENIER
Life of this patent
Estimating the term…
Abstract
The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications.
Claims16
An antibody or an antigen-binding fragment thereof, which specifically binds to CD127, in particular to human CD127, comprising:
- an antibody light chain comprising or an antibody light chain variable domain consisting of a sequence selected from the group consisting of SEQ ID No:
- 9;
- SEQ ID No:
- 10;
- SEQ ID No:
- 11;
- SEQ ID No:
- 12;
- in particular SEQ ID No:
- 12;
- and
- an antibody heavy chain variable domain comprising the three CDRs consisting of the sequences set forth in SEQ ID No:
- 1, SEQ ID No:
- 2, and SEQ ID No:
- 3, in particular an antibody heavy chain variable domain consisting of the sequence set forth in SEQ ID No:
- 7.
A method of selecting a compound from the group consisting of an antibody, an antigen-binding fragment thereof or an antibody mimetic molecule and comprising or consisting of at least one of the following steps:
- i. testing the binding capacity of the compound to CD127, in particular to human CD127, in particular to an epitope sequence from domain D1 and/or from site 2b of domain D2 of human CD127;
- ii. testing the inhibition of IL7-R signalling induced by IL7, in particular STAT-5 phosphorylation, in presence of the compound;
- iii. testing the activation of the phosphatidylinositol 3-kinase in presence of the compound;
- iv. testing the activation of the ERK signalling pathway in presence of the compound;
- v. testing the binding capacity of the compound to at least the third beta sheet of the site 2b of CD127, in particular to human CD127;
- and optionally further comprising at least one of the following steps:
- vi. testing the binding of CD127 to the γc common chain of cytokine receptors in presence of the compound;
- vii. testing the internalization of CD127 and/or IL7-induced internalization of CD127 in presence of the compound;
- viii. testing the maturation of dendritic cells induced by TSLP in presence of the compound;
- particularly wherein the compound which specifically binds to CD127 is an antagonist of IL-7R signalling induced by IL-7 and which does not induce the activation of the phosphatidylinositol 3-kinase and/or the ERK signalling pathway is selected.
Dependencies are inferred from the claim text.